Denali Therapeutics, Inc. (DNLI)
20.17
+0.42
(+2.13%)
USD |
NASDAQ |
Mar 20, 16:00
20.35
+0.18
(+0.89%)
After-Hours: 20:00
Denali Therapeutics Research and Development Expense (Quarterly) : 97.90M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Protalix Biotherapeutics, Inc. | 5.635M |
| Agenus, Inc. | 7.511M |
| Curis, Inc. | 5.825M |
| Plus Therapeutics, Inc. | 2.941M |
| Windtree Therapeutics, Inc. | 1.537M |